Literature DB >> 1330589

Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist.

A Nagahisa1, Y Kanai, O Suga, K Taniguchi, M Tsuchiya, J A Lowe, H J Hess.   

Abstract

CP-96,345, a potent non-peptide antagonist of the substance P (SP) receptor, inhibited SP-, neurokinin A (NKA)- and neurokinin B-induced plasma extravasation in guinea pig dorsal skin. The inhibition was specific for the three tachykinins; CP-96,345 was not active against plasma leakage caused by histamine, bradykinin, platelet-activating factor or leukotriene D4. CP-96,345 inhibited capsaicin-induced plasma extravasation in the ureter, an inflammatory response caused by neuropeptides released from afferent C-fibers. Thus, the NK1 receptor appears to play a major role in vascular permeability increases induced by exogenous and endogenous tachykinins. In contrast, CP-96,345 was inactive against SP- and NKA-induced contraction of guinea pig ureter, suggesting that the smooth muscle contraction is not NK1-mediated. CP-96,345 exhibited analgesic activity in acetic acid-induced abdominal stretching in mice, indicating for the first time that SP plays a critical role in this model. The results of these studies support a pathophysiological role of SP and NK1 receptor under acute neurogenic inflammatory conditions and in pain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330589     DOI: 10.1016/0014-2999(92)90847-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Modulation of carrageenan-induced hind paw edema by substance P.

Authors:  J P Gilligan; S J Lovato; M D Erion; A Y Jeng
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

2.  NK1 receptors mediate tachykinin-induced plasma extravasation in the rat knee joint.

Authors:  Y Hirayama; R Yasumitsu; A Kawamura; T Fujii
Journal:  Agents Actions       Date:  1993-11

3.  Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.

Authors:  E Cellier; L Barbot; S Iyengar; R Couture
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators.

Authors:  D T Walsh; V B Weg; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580.

Authors:  N M Rupniak; S Boyce; A R Williams; G Cook; J Longmore; G R Seabrook; M Caeser; S D Iversen; R G Hill
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  An isobolographic analysis of the effects of N-methyl-D-aspartate and NK1 tachykinin receptor antagonists on inflammatory hyperalgesia in the rat.

Authors:  K Ren; M J Iadarola; R Dubner
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation.

Authors:  A Nagahisa; R Asai; Y Kanai; A Murase; M Tsuchiya-Nakagaki; T Nakagaki; T C Shieh; K Taniguchi
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

8.  Effect of RP 67580, a non-peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat.

Authors:  J M Laird; R J Hargreaves; R G Hill
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

9.  Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.

Authors:  W S Lee; S M Moussaoui; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

10.  The anti-inflammatory action of maropitant in a mouse model of acute pancreatitis.

Authors:  Atsushi Tsukamoto; Minami Ohgoda; Nozomi Haruki; Masatoshi Hori; Tomo Inomata
Journal:  J Vet Med Sci       Date:  2018-01-16       Impact factor: 1.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.